Newamsterdam Pharma Co. NV-27NAMSWPreferred / convertible
13F holders, Q4 2025 (December 31)9holders
1new positions
1sold out
$23.04avg. 13F price*
At the end of Q4 2025, 9 institutions reported holding Newamsterdam Pharma Co. NV-27 (NAMSW) in their 13F filings, unchanged from Q3 2025. 1 opened new positions and 1 sold out. The largest holders were Frazier Life Sciences Management, L.P. ($11.5M), Ra Capital Management, L.P. ($7.7M) and Affinity Asset Advisors, LLC ($5.6M).
- Company
- Newamsterdam Pharma Co. NV-27
- CUSIP
- N62509117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $397K |
| Exits | 1 | $285K |
All 13F filers, Q3 2025 → Q4 2025: 15,708 shares bought and 17,033 shares sold, net −1,325 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Frazier Life Sciences Management, L.P. | — | No change | 500,333 | $11.5M |
| Ra Capital Management, L.P. | — | No change | 333,333 | $7.7M |
| Affinity Asset Advisors, LLC | — | No change | 245,000 | $5.6M |
| Bain Capital Life Sciences Investors, LLC | — | Reduce 0.0% | 99,999 | $2.3M |
| Deerfield Management Company, L.P. | — | No change | 92,787 | $2.1M |
| Aristeia Capital, L.L.C. | — | New | 15,708 | $397K |
| Vestcor Inc | — | No change | 9,632 | $239K |
| CIBC Private Wealth Group LLC | — | Reduce -20.0% | 1,000 | $25K |
| UBS Group AG | — | Reduce -22.7% | 396 | $9K |
"% of holder's portfolio" is NAMSW's weight in each manager's 13F, not the share of Newamsterdam Pharma Co. NV-27 the manager owns.